As of March 23, 2026, Edgewise Therapeutics's top three insider holders are Holdings A/S Novo (TenPercentOwner, 6.07Mn shares), Advisors Llc Orbimed (Director, 443.79K shares), Peter A. Thompson (Director, 443.79K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Holdings A/S Novo | 6,071,703 | 0 | 16 Sep, 2022 | |
| Peter A. Thompson | 0 | 443,792 | 04 Apr, 2025 | |
| Advisors Llc Orbimed | 0 | 443,792 | 04 Apr, 2025 | |
| R Michael Carruthers | Chief Financial Officer | 86,162 | 0 | 14 Aug, 2025 |
| Kevin Koch | President And Ceo | 30,615 | 0 | 14 Aug, 2025 |
| Joanne M. Donovan | Cmo | 25,361 | 0 | 14 Aug, 2025 |
| Jonathan C Fox | 24,175 | 0 | 05 Jan, 2026 | |
| Behrad Derakhshan | Chief Business Officer | 23,645 | 0 | 14 Aug, 2025 |
| Alan J Russell | Chief Scientific Officer | 23,400 | 0 | 13 Nov, 2025 |
| Badreddin Edris | 19,820 | 0 | 21 Jan, 2026 | |
| John R Moore | General Counsel | 10,214 | 0 | 14 Aug, 2025 |
| Marc Semigran | Chief Development Officer | 6,716 | 0 | 27 Dec, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 21 Jan, 2026 | Badreddin Edris | Common Stock | A | 13,690 | $0.39 | 33,510 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | A | 17,236 | $0.64 | 50,746 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | A | 10,463 | $1.93 | 61,209 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | A | 66,477 | $1.93 | 127,686 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | A | 7,605 | $0.71 | 135,291 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | D | 13,690 | $29.44 | 121,601 | D | S |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | D | 17,236 | $29.44 | 104,365 | D | S |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | D | 7,605 | $29.44 | 96,760 | D | S |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | D | 10,463 | $29.44 | 86,297 | D | S |
| 21 Jan, 2026 | Badreddin Edris | Common Stock | D | 66,477 | $29.44 | 19,820 | D | S |
| 21 Jan, 2026 | Badreddin Edris | Stock Option (Right to Buy) | D | 10,463 | $0.00 | 0 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Stock Option (Right to Buy) | D | 66,477 | $0.00 | 0 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Stock Option (Right to Buy) | D | 7,605 | $0.00 | 0 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Stock Option (Right to Buy) | D | 17,236 | $0.00 | 0 | D | M |
| 21 Jan, 2026 | Badreddin Edris | Stock Option (Right to Buy) | D | 13,690 | $0.00 | 0 | D | M |
| 02 Jan, 2026 | Jonathan C Fox | Common Stock | A | 473 | $0.00 | 24,175 | D | A |
| 19 Nov, 2025 | Christopher Nathan Martin | Stock Options (Right to buy) | A | 45,150 | $0.00 | 45,150 | D | A |
| 11 Nov, 2025 | Jonathan C Fox | Common Stock | A | 10,700 | $18.64 | 23,702 | D | P |
| 10 Nov, 2025 | Michael Nofi | Restricted Stock Units | A | 43,750 | $0.00 | 43,750 | D | A |
| 12 Nov, 2025 | Alan J Russell | Common Stock | A | 100,000 | $0.18 | 123,400 | D | M |